Givaudan (SWX:GIVN) is back in focus after J.P. Morgan placed the fragrance and flavours specialist on Positive Catalyst Watch, and Barclays upgraded the stock ahead of its October 13 third quarter update.
The recent analyst calls come after a mixed stretch for Givaudan, with the 30 day share price return of 4.68% pointing to firmer short term momentum, while the year to date share price return of 9.53% sits alongside a 3 year total shareholder return of 24.17%.
Spot fresh ideas riding similar momentum to Givaudan by scanning our hand-picked 185 high quality undervalued stocks that combine solid fundamentals with market skepticism.
After a sharp swing back into favour and fresh optimism on Givaudan's outlook, the real test now is simple. Are buyers still being paid enough for the risk at today's price, once the valuation is stripped back?
Most Popular Narrative: 2% Undervalued
On the most followed narrative, Givaudan screens just below estimated fair value, with a CHF3,468 fair value against a last close of CHF3,402. The gap is narrow, so the real story hinges on how its growth engines and risk factors line up against that modest discount.
The company continues to outpace industry peers, in part due to its innovation pipeline: launches of sustainable, natural ingredients (e.g., FDA-approved color solutions, algae-derived beauty actives) directly align with consumer shifts toward health, wellness, and clean label products, supporting both top-line growth and potential margin expansion.
See why 22 investors see Givaudan as 2% undervalued .
Result: Fair Value of CHF3,468 (UNDERVALUED)
Still, the bullish Givaudan story hinges on free cash flow recovering, and on margin pressure from input costs and tariffs not biting harder than analysts expect.
Find out about the key risks to this Givaudan narrative .
Another View on Givaudan's Valuation
The SWS DCF model presents a different perspective on Givaudan. On that framework, the share price of CHF3,402 stands well below an estimated future cash flow value of CHF4,400.53, which appears undervalued on this basis. This raises a question: which matters more to you, near-term earnings multiples or the long-run cash flow profile?
Look into how the SWS DCF model arrives at its fair value.
Next Steps
Mixed signals on Givaudan's value and risk profile create plenty of room for debate, so move fast, review the data, and weigh both sides using 3 key rewards and 1 important warning sign
Looking for more investment ideas beyond Givaudan?
Do not stop with a single stock. Use powerful screeners to quickly surface other opportunities that match your risk tolerance and preferred style of investing.
-
Target resilient balance sheets by scanning a curated list of solid balance sheet and fundamentals (206 results) that filters for financial strength when markets turn jumpy.
-
Hunt for quality at a discount through our focused 185 high quality undervalued stocks designed to highlight companies where fundamentals and pricing look out of sync.
-
Spot potential income pillars by reviewing a hand picked 162 dividend fortresses that concentrates on higher yielding payouts with supporting fundamentals.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include GIVN.SW .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
